{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:58:13Z","timestamp":1791021493922,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.rmed.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T14:21:12Z","timestamp":1515594072000},"page":"62-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Aspirin exacerbated respiratory disease: Current topics and trends"],"prefix":"10.1016","volume":"135","author":[{"given":"Jos\u00e9 Carlos","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Judith","family":"Moreno-Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Manuel","family":"Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-5511","authenticated-orcid":false,"given":"Eduardo","family":"Guan\u00ed-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2018.01.002_bib1","first-page":"189","article-title":"Anaphylaxie et Idiosyncrasie","volume":"30","author":"Widal","year":"1922","journal-title":"Presse Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib2","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-68-5-975","article-title":"Intolerance to aspirin clinical studies and consideration of its pathogenesis","volume":"68","author":"Samter","year":"1968","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1067\/mai.2002.123024","article-title":"Sinusitis and asthma: entering the realm of evidence-based medicine","volume":"109","author":"Borrish","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1385\/CRIAI:24:2:113","article-title":"Natural history and clinical features of aspirin-exacerbated respiratory disease","volume":"24","author":"Fahrenholz","year":"2003","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1398-9995.1997.tb01039.x","article-title":"Mechanism of aspirin-induced asthma","volume":"52","author":"Szczeklik","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/JAA.S88739","article-title":"Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances","volume":"9","author":"Steinke","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/1744666X.2015.1039940","article-title":"Aspirin-exacerbated respiratory disease: characteristics and management strategies","volume":"11","author":"Simon","year":"2015","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaci.2006.07.024","article-title":"Clinical and pathologic perspectives on aspirin sensitivity and asthma","volume":"118","author":"Stevenson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62084-4","article-title":"The natural history and clinical characteristics of aspirin-exacerbated respiratory disease","volume":"89","author":"Berges-Gimeno","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib10","first-page":"177","article-title":"Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes","volume":"87","author":"Stevenson","year":"2001","journal-title":"Aaai"},{"key":"10.1016\/j.rmed.2018.01.002_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOO.0b013e3283450102","article-title":"Role of aspirin desensitization in the management of chronic rhinosinusitis","volume":"19","author":"Rizk","year":"2011","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.rmed.2018.01.002_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease \u2014 new prime suspects","author":"Laidlaw","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib13","first-page":"432","article-title":"Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol"},{"key":"10.1016\/j.rmed.2018.01.002_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4168\/aair.2015.7.4.312","article-title":"Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice?","volume":"7","author":"Kowalski","year":"2015","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2500\/ajra.2015.29.4123","article-title":"Factors driving the aspirin exacerbated respiratory disease phenotype","volume":"29","author":"Steinke","year":"2015","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/ACI.0000000000000122","article-title":"Upper airways in aspirin-exacerbated respiratory disease","volume":"15","author":"Choi","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2011.3.1.3","article-title":"Aspirin-exacerbated respiratory disease: evaluation and management","volume":"3","author":"Lee","year":"2011","journal-title":"Allergy. Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/all.12629","article-title":"NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity","volume":"70","author":"Morales","year":"2015","journal-title":"Allergy Eur. J. Allergy Clin. Immunol"},{"key":"10.1016\/j.rmed.2018.01.002_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thorax.57.7.569","article-title":"The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients","volume":"57","author":"Vally","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.01.002_bib20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaip.2016.05.016","article-title":"Aspirin-exacerbated respiratory disease: not always ``adult-onset\u2019\u2019","volume":"4","author":"Tuttle","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract"},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2018.01.002_bib22","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1136\/thorax.55.suppl_2.S42","article-title":"Clinical features and diagnosis of aspirin induced asthma","volume":"55","author":"Szczeklik","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.01.002_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/817910","article-title":"Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination","volume":"2012","author":"Graefe","year":"2012","journal-title":"J. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bjorl.2015.04.010","article-title":"The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD)","volume":"82","author":"Spies","year":"2016","journal-title":"Braz. J. Otorhinolaryngol"},{"key":"10.1016\/j.rmed.2018.01.002_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00408-016-9852-9","article-title":"Association of TRPM3 polymorphism (rs10780946) and aspirin-exacerbated respiratory disease (AERD)","volume":"194","author":"Narayanankutty","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.rmed.2018.01.002_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.rmed.2008.03.017","article-title":"Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma","volume":"102","author":"Palikhe","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.12.218","article-title":"Clinical characteristics of respiratory disease","author":"Stevenson","year":"2016","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2018.01.002_bib28","first-page":"14","article-title":"Smoking, environmental tobacco smoke, and aspirin-exacerbated respiratory disease","volume":"108","author":"Chang","year":"2012","journal-title":"ANAI"},{"key":"10.1016\/j.rmed.2018.01.002_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11882-009-0023-4","article-title":"Aspirin sensitivity and desensitization for asthma and sinusitis","volume":"9","author":"Stevenson","year":"2009","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.rmed.2018.01.002_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2222.1988.tb02838.x","article-title":"Aspirin-induced asthma as a viral disease","volume":"18","author":"Szczeklik","year":"1988","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-015-0569-2","article-title":"Aspirin-exacerbated diseases: advances in asthma with nasal polyposis, urticaria, angioedema, and anaphylaxis","volume":"15","author":"Stevens","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.rmed.2018.01.002_bib33","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jaip.2015.06.013","article-title":"An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease","volume":"3","author":"Chen","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1016\/j.rmed.2018.01.002_bib34","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-015-0552-y","article-title":"Hypersensitivity to aspirin and other NSAIDs\u202f: diagnostic approach in patients with chronic rhinosinusitis, curr","author":"Makowska","year":"2015","journal-title":"Allergy Asthma Rep"},{"key":"10.1016\/j.rmed.2018.01.002_bib35","unstructured":"C. Jenkins, J. Costello, L. Hodge, Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice, i (n.d.) 1\u20137."},{"key":"10.1016\/j.rmed.2018.01.002_bib36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.rmed.2015.02.015","article-title":"Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease","volume":"109","author":"Bochenek","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1385\/CRIAI:24:2:159","article-title":"Aspirin desensitization in patients with AERD","volume":"24","author":"Stevenson","year":"2003","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib38","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2005.08.035","article-title":"Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma","volume":"116","author":"Mascia","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/thorax.55.suppl_2.S84","article-title":"Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?","volume":"55","author":"Kowalski","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.01.002_bib40","first-page":"163","article-title":"Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease","volume":"33","author":"Mullol","year":"2013","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2018.01.002_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2500\/ajr.2007.21.3108","article-title":"Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis","volume":"21","author":"Young","year":"2007","journal-title":"Am. J. Rhinol."},{"key":"10.1016\/j.rmed.2018.01.002_bib42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S1081-1206(10)61323-3","article-title":"Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease","volume":"94","author":"Mascia","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2005.12.053","article-title":"The broken balance in aspirin hypersensitivity,","volume":"533","author":"Szczeklik","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.rmed.2018.01.002_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1081-1206(10)62468-4","article-title":"Nasal polyposis: clinical course during 20 years","volume":"85","author":"Vento","year":"2000","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2500\/ajr.2006.20.2913","article-title":"Medical and surgical considerations in patients with Samter's triad","volume":"20","author":"McMains","year":"2006","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.03.022","article-title":"Biology of nasal polyposis","volume":"133","author":"Stevens","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2500\/ajr.2007.21.2909","article-title":"Intracranial polyps in patients with Samter's triad","volume":"21","author":"Majithia","year":"2007","journal-title":"Am. J. Rhinol."},{"key":"10.1016\/j.rmed.2018.01.002_bib48","series-title":"Aural Polyps in Samter \u2019 s Triad\u202f: Case Report and Literature Review","first-page":"774","author":"Shen","year":"2012"},{"key":"10.1016\/j.rmed.2018.01.002_bib49","first-page":"719","article-title":"When surgery, antibiotics, and steroids fail to resolve chronic rhinosinusitis","volume":"29","author":"Ferguson","year":"2009","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2018.01.002_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1183\/09031936.93.02020127","article-title":"Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation","volume":"2","author":"Picado","year":"1989","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.01.002_bib51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2016.04.028","article-title":"Eosinophilia-associated coronary artery vasospasm in patients with aspirin-exacerbated respiratory disease","volume":"4","author":"Shah","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1016\/j.rmed.2018.01.002_bib52","first-page":"147","article-title":"Aspirin-Exacerbated Respiratory D i s e a s e","volume":"33","author":"Bochenek","year":"2013","journal-title":"Clinical Disease and Diagnosis"},{"key":"10.1016\/j.rmed.2018.01.002_bib53","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0091-6749(95)70290-3","article-title":"Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects","volume":"96","author":"Settipane","year":"1995","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib54","first-page":"67","article-title":"Safety of selective COX-2 inhibitors in aspirin\/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of","volume":"41","author":"Bavbek","year":"2004"},{"key":"10.1016\/j.rmed.2018.01.002_bib55","series-title":"Safety of Meloxicam in Aspirin-hypersensitive Patients with Asthma and\/or Nasal Polyps","first-page":"64","author":"Bavbek","year":"2007"},{"key":"10.1016\/j.rmed.2018.01.002_bib56","series-title":"Tolerability to Nabumetone and Meloxicam in Patients with Nonsteroidal Anti-inflammatory Drug Intolerance","first-page":"960","author":"Prieto","year":"2007"},{"key":"10.1016\/j.rmed.2018.01.002_bib57","first-page":"81","article-title":"Tolerability of nimesulide in patients with histories of adverse reactions to acetylsalicylic acid and nonsteroidal anti-inflammatory drugs","author":"Tepetam","year":"2014","journal-title":"Nobel Med"},{"key":"10.1016\/j.rmed.2018.01.002_bib58","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1378\/chest.121.6.1812","article-title":"Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma","volume":"121","author":"Mart\u00edn-Garc\u00eda","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.01.002_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1081-1206(10)61378-6","article-title":"Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"97","author":"El Miedany","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000322841","article-title":"Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"156","author":"Valero","year":"2011","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2222.2001.01075.x","article-title":"Safety of a specific COX-2 inhibitor in aspirin-induced asthma","volume":"31","author":"Szczeklik","year":"2001","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mai.2001.116290","article-title":"Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma","volume":"108","author":"Stevenson","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib63","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/art.10426","article-title":"The safety of celecoxib in patients with aspirin-sensitive asthma","volume":"46","author":"Woessner","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmed.2018.01.002_bib64","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1067\/mai.2003.1450","article-title":"Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib","volume":"111","author":"Gyllfors","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2005.10.021","article-title":"Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen","volume":"117","author":"Baldassarre","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaip.2013.12.003","article-title":"Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease","volume":"2","author":"Cardet","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1016\/j.rmed.2018.01.002_bib67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11882-017-0673-6","article-title":"Update on aspirin-exacerbated respiratory disease","volume":"17","author":"Woessner","year":"2017","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.rmed.2018.01.002_bib68","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1016\/j.rmed.2018.01.002_bib69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4168\/aair.2016.8.4.298","article-title":"Update on the management of aspirin-exacerbated respiratory disease","volume":"8","author":"Buchheit","year":"2016","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.anai.2010.12.016","article-title":"Aspirin-exacerbated respiratory disease: is it in our DNA?","volume":"106","author":"Chang","year":"2011","journal-title":"Ann. Allergy, Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib71","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1398-9995.2010.02514.x","article-title":"Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics","volume":"66","author":"Cheong","year":"2011","journal-title":"Allergy Eur. J. Allergy Clin. Immunol"},{"key":"10.1016\/j.rmed.2018.01.002_bib72","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1398-9995.2009.02158.x","article-title":"Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease","volume":"65","author":"Palikhe","year":"2010","journal-title":"Allergy Eur. J. Allergy Clin. Immunol"},{"key":"10.1016\/j.rmed.2018.01.002_bib73","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4168\/aair.2014.6.4.288","article-title":"Cysteinyl leukotrienes and their receptors; emerging concepts","volume":"6","author":"Kanaoka","year":"2014","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2332\/allergolint.O-08-545","article-title":"Correlation between the prostaglandin D2\/E2 ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma","volume":"57","author":"Yoshimura","year":"2008","journal-title":"Allergol. Int."},{"key":"10.1016\/j.rmed.2018.01.002_bib75","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma","volume":"101","author":"Cowburn","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.rmed.2018.01.002_bib76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaci.2005.02.029","article-title":"Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis","volume":"115","author":"P\u00e9rez-Novo","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2011.01.065","article-title":"Reduced expression of COXs and production of prostaglandin E2 in patients with nasal polyps with or without aspirin-intolerant asthma","volume":"128","author":"Roca-Ferrer","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib78","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000329744","article-title":"Expression of arachidonate metabolism enzymes and receptors in nasal polyps of aspirin-hypersensitive asthmatics","volume":"157","author":"Adamusiak","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib79","doi-asserted-by":"crossref","first-page":"16987","DOI":"10.1073\/pnas.1313185110","article-title":"Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.rmed.2018.01.002_bib80","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1067\/mai.2003.67","article-title":"Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma","volume":"111","author":"Steinke","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib81","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jaci.2015.02.005","article-title":"Platelets in aspirin-exacerbated respiratory disease","volume":"135","author":"Laidlaw","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib82","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/lary.21969","article-title":"Evidence for distinct histologic profile of nasal polyps with and without eosinophilia","volume":"121","author":"Payne","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.rmed.2018.01.002_bib83","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1034\/j.1399-3003.1999.14c21.x","article-title":"Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis","volume":"14","author":"Varga","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.01.002_bib84","series-title":"Nasal Polyposis: from Cytokines to Growth","first-page":"279","author":"Bachert","year":"2015"},{"key":"10.1016\/j.rmed.2018.01.002_bib85","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/cea.12096","article-title":"Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD","volume":"43","author":"Choi","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4049\/jimmunol.1301753","article-title":"Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease","volume":"193","author":"Steinke","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib87","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rmed.2018.01.002_bib88","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/0091-6749(94)90123-6","article-title":"Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma","volume":"94","author":"Fischer","year":"1994","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib89","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.clinbiochem.2012.12.005","article-title":"Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD)","volume":"46","author":"Narayanankutty","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.rmed.2018.01.002_bib90","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0400235101","article-title":"Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis","volume":"101","author":"Beller","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.rmed.2018.01.002_bib91","first-page":"1493","article-title":"Leukotriene-receptor expression on nasal mucosal inflammatory","volume":"347","author":"Rhinosinusitis","year":"2002"},{"key":"10.1016\/j.rmed.2018.01.002_bib92","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaci.2004.10.051","article-title":"Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis","volume":"115","author":"Corrigan","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib93","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.4049\/jimmunol.168.11.5811","article-title":"Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4\/MyD88\/NF-IL6 pathway","volume":"168","author":"Uematsu","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib94","doi-asserted-by":"crossref","first-page":"37937","DOI":"10.1074\/jbc.M305108200","article-title":"Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2","volume":"278","author":"Murakami","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.rmed.2018.01.002_bib95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaci.2015.09.028","article-title":"Low E-prostanoid 2 receptor levels and deficient induction of the IL-1\u03b2\/IL-1 type i receptor\/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Machado-Carvalho","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2005.10.037","article-title":"Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells","volume":"117","author":"Ying","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12931-014-0100-7","article-title":"Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis\/nasal polyps with and without aspirin hypersensitivity","volume":"15","author":"Machado-Carvalho","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib98","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjp.0706664","article-title":"Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation","volume":"147","author":"Kay","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.rmed.2018.01.002_bib99","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jaci.2015.04.002","article-title":"Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor","volume":"136","author":"S\u00e4fholm","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/mol.62.2.250","article-title":"Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils","volume":"62","author":"Flamand","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.rmed.2018.01.002_bib101","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.110.174821","article-title":"Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors","volume":"336","author":"Petrucci","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.rmed.2018.01.002_bib102","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.4049\/jimmunol.181.10.7273","article-title":"Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors","volume":"181","author":"Sturm","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.12.1034","article-title":"Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease","volume":"133","author":"Laidlaw","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib104","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.160.1.9808048","article-title":"Cyclooxygenase-2 mRNA is down expressed in nasal polyps from aspirin-sensitive asthmatics","volume":"160","author":"Picado","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2332\/allergolint.08-RAI-0033","article-title":"Role of prostaglandin D(2) and its receptors in the pathophysiology of asthma","volume":"57","author":"Oguma","year":"2008","journal-title":"Allergol. Int."},{"key":"10.1016\/j.rmed.2018.01.002_bib106","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/09031936.95.08030411","article-title":"Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor","volume":"8","author":"Johnston","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.01.002_bib107","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.05.008","article-title":"Prominent role of interferon-\u03b3 in aspirin-exacerbated respiratory disease","volume":"132","author":"Steinke","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib110","first-page":"706","article-title":"Cytokine expression in peripheral blood lymphocytes before and after aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"28","author":"Kennedy","year":"2007"},{"key":"10.1016\/j.rmed.2018.01.002_bib111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1084\/jem.193.1.123","article-title":"T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4","volume":"193","author":"Hsieh","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib112","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.4049\/jimmunol.167.5.2855","article-title":"IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages","volume":"167","author":"Thivierge","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib113","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1165\/rcmb.2006-0252OC","article-title":"Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-?? on peripheral immune cells","volume":"36","author":"Early","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2018.01.002_bib114","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaci.2009.07.031","article-title":"Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization","volume":"124","author":"Steinke","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.anai.2016.11.004","article-title":"Interleukin 16 and CCL17\/thymus and activation-regulated chemokine in patients with aspirin-exacerbated respiratory disease","volume":"118","author":"Teran","year":"2017","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib116","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib117","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1067\/mai.2003.1387","article-title":"A controlled study of 9\u03b1,11\u03b2-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge","volume":"111","author":"Bochenek","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib118","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI59262","article-title":"Niacin and biosynthesis of PGD 2 by platelet COX-1 in mice and humans","volume":"122","author":"Song","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.rmed.2018.01.002_bib119","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4168\/aair.2013.5.5.258","article-title":"Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways","volume":"5","author":"Park","year":"2013","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib120","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaci.2003.12.012","article-title":"HLa association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population [3]","volume":"113","author":"Choi","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib121","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00438-012-0685-9","article-title":"Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD","volume":"287","author":"Shin","year":"2012","journal-title":"Mol. Genet. Genom."},{"key":"10.1016\/j.rmed.2018.01.002_bib122","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1081-1206(10)60465-6","article-title":"Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis","volume":"100","author":"Dursun","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib123","series-title":"Allergy Princ. Pract.","first-page":"1058","article-title":"Sensivity to aspirin a non steroideal antiinflammatory drugs","author":"Donald","year":"1998"},{"key":"10.1016\/j.rmed.2018.01.002_bib124","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3349\/ymj.2009.50.6.744","article-title":"Update on recent advances in the management of aspirin exacerbated respiratory disease","volume":"50","author":"Palikhe","year":"2009","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.rmed.2018.01.002_bib125","first-page":"1111","article-title":"EAACI\/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity","volume":"2","author":"Nizankowska-Mogilnicka","year":"2007"},{"key":"10.1016\/j.rmed.2018.01.002_bib126","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2500\/ajra.2016.30.4370","article-title":"Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future","volume":"30","author":"Kennedy","year":"2016","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib127","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2008.09.048","article-title":"Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease","volume":"123","author":"Hope","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0091-6749(98)70163-0","article-title":"Nasal provocation test with lysine-aspirin for diagnosis of aspirin- sensitive asthma","volume":"101","author":"Milewski","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib129","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2500\/aap.2013.34.3670","article-title":"The clinical dilemma of \u201csilent desensitization\u201d in aspirin-exacerbated respiratory disease","volume":"34","author":"White","year":"2013","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.rmed.2018.01.002_bib130","first-page":"13","article-title":"Pathogenesis, diagnosis, and treatment of aspirin","volume":"99","author":"Jenneck","year":"2007"},{"key":"10.1016\/j.rmed.2018.01.002_bib131","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/thorax.55.11.921","article-title":"Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry","volume":"55","author":"Casadevall","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.01.002_bib132","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1034\/j.1398-9995.2002.t01-1-13447.x","article-title":"Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA)","volume":"57","author":"Alonso-Llamazares","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib133","series-title":"Current Management of Aspirin- Exacerbated Respiratory Disease","author":"Scadding","year":"2012"},{"key":"10.1016\/j.rmed.2018.01.002_bib134","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000082586","article-title":"A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs","volume":"136","author":"Sanz","year":"2005","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4168\/aair.2012.4.3.137","article-title":"Flow cytometry-assisted basophil activation test as a safe diagnostic tool for aspirin\/NSAID hypersensitivity","volume":"4","author":"Kim","year":"2012","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib136","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1398-9995.2005.00836.x","article-title":"Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive aspirin-sensitive patients identification test (ASPITest)","volume":"60","author":"Kowalski","year":"2005","journal-title":"Allergy Eur. J. Allergy Clin. Immunol"},{"key":"10.1016\/j.rmed.2018.01.002_bib137","unstructured":"M.L. Kowalski, R. Pawliczak, J. Wozniak, K. Siuda, M. Poniatowska, J. Iwaszkiewicz, T. Kornatowski, M.A. Kaliner, Differential Metabolism of Arachidonic Acid in Nasal Polyp Epithelial Cells Cultured from Aspirin-sensitive and Aspirin-tolerant Patients, (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib138","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1034\/j.1398-9995.2001.00103.x","article-title":"Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions","volume":"56","author":"Lebel","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib139","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.anai.2015.12.026","article-title":"Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease","volume":"116","author":"Jerschow","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib140","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaip.2016.11.004","article-title":"Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta-analysis","volume":"5","author":"Hagan","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1016\/j.rmed.2018.01.002_bib141","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/all.12512","article-title":"Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity","volume":"69","author":"Mastalerz","year":"2014","journal-title":"Allergy Eur. J. Allergy Clin. Immunol"},{"key":"10.1016\/j.rmed.2018.01.002_bib142","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2010.12.1108","article-title":"Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype","volume":"127","author":"Sanak","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib143","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib144","doi-asserted-by":"crossref","first-page":"36599","DOI":"10.1038\/srep36599","article-title":"Exploration of the sphingolipid metabolite, sphingosine-1-phosphate and sphingosine, as novel biomarkers for aspirin-exacerbated respiratory disease","volume":"6","author":"Trinh","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2018.01.002_bib145","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1365-2222.2004.02051.x","article-title":"Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma","volume":"34","author":"Suh","year":"2004","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000076832","article-title":"Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship","volume":"133","author":"P\u00e9rez-Novo","year":"2004","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib147","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0194599814555836","article-title":"Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study","volume":"152","author":"Sommer","year":"2015","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.rmed.2018.01.002_bib148","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.2500\/ajra.2015.29.4220","article-title":"Dietary modifications for refractory chronic rhinosinusitis? Manipulating diet for the modulation of inflammation","volume":"29","author":"Nayan","year":"2015","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib149","first-page":"385","article-title":"A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial","volume":"6","author":"Doron","year":"2016"},{"key":"10.1016\/j.rmed.2018.01.002_bib150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.201000408","article-title":"A systematic review of salicylates in foods: estimated daily intake of a Scottish population","volume":"55","author":"Wood","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib151","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0002-8223(21)03743-3","article-title":"Salicylates in foods","volume":"85","author":"Swain","year":"1985","journal-title":"J. Am. Diet Assoc."},{"key":"10.1016\/j.rmed.2018.01.002_bib152","unstructured":"High Omega-3\/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02064738. (Accessed 23 June 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib153","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1365-2133.2008.08830.x","article-title":"Control of salicylate intolerance with fish oils","volume":"159","author":"Healy","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.rmed.2018.01.002_bib154","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MOO.0b013e32834dfa80","article-title":"Nasal irrigation with or without drugs: the evidence","volume":"20","author":"Adappa","year":"2012","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.rmed.2018.01.002_bib155","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1398-9995.1997.tb01248.x","article-title":"Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma","volume":"52","author":"Mastalerz","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib156","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1046\/j.1365-2745.2002.01501.x","article-title":"The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions","volume":"32","author":"Berges-Gimeno","year":"2002","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib157","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2500\/ajra.2013.27.3976","article-title":"Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review","volume":"27","author":"Wentzel","year":"2013","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib158","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","article-title":"Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial","volume":"165","author":"Dahl\u00e9n","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib159","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1164\/ajrccm.157.4.9707089","article-title":"Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics","volume":"157","author":"Dahl\u00e9n","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.otc.2016.08.007","article-title":"Aspirin-exacerbated respiratory disease","volume":"50","author":"Walgama","year":"2017","journal-title":"Otolaryngol. Clin."},{"key":"10.1016\/j.rmed.2018.01.002_bib161","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.otohns.2008.05.628","article-title":"A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis","volume":"139","author":"Joe","year":"2008","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.rmed.2018.01.002_bib162","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2500\/ajra.2015.29.4223","article-title":"Oral corticosteroids in the management of chronic rhinosinusitis with and without nasal polyps: risks and benefits","volume":"29","author":"Poetker","year":"2015","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmed.2018.01.002_bib163","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0194599814545750","article-title":"Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease","volume":"151","author":"Cho","year":"2014","journal-title":"Otolaryngology-Head Neck Surg"},{"key":"10.1016\/j.rmed.2018.01.002_bib164","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"Berges-Gimeno","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib165","first-page":"735","article-title":"Mechanisms of benefit with aspirin therapy in aspirin-exacerbated respiratory disease","volume":"36","author":"Hill","year":"2016","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2018.01.002_bib166","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1081-1206(10)61803-0","article-title":"Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"90","author":"Berges-Gimeno","year":"2003","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib167","first-page":"1","article-title":"Current complications and treatment of aspirin- exacerbated respiratory disease","volume":"0","author":"Cook","year":"2016","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.rmed.2018.01.002_bib168","first-page":"503","article-title":"Chronic rhinosinusitis and aspirin-exacerbated respiratory disease","volume":"36","author":"Dunn","year":"2016","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2018.01.002_bib169","series-title":"Outcome Analysis of Endoscopic Sinus Surgery in Patients with Nasal Polyps and Asthma","first-page":"1703","author":"Batra","year":"2003"},{"key":"10.1016\/j.rmed.2018.01.002_bib170","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/MLG.0b013e318170af1e","article-title":"Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma?","volume":"118","author":"Awad","year":"2008","journal-title":"Laryngoscope"},{"key":"10.1016\/j.rmed.2018.01.002_bib171","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/000348941112000304","article-title":"Revision rates after endoscopic sinus surgery: a recurrence analysis","volume":"120","author":"Mendelsohn","year":"2011","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.rmed.2018.01.002_bib172","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2500\/ajr.2006.20.2913","article-title":"Medical and surgical considerations in patients with Samter's triad","volume":"20","author":"Mc Mains","year":"2006","journal-title":"Am. J. Rhinol."},{"key":"10.1016\/j.rmed.2018.01.002_bib173","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1081-1206(10)61101-5","article-title":"Effect of leukotriene modifier drugs on the safety of oral aspirin challenges","volume":"97","author":"White","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib174","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1081-1206(10)60692-8","article-title":"Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper","volume":"98","author":"Macy","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib175","series-title":"Selection of Aspirin Dosages for Aspirin Desensitization Treatment in Patients with Aspirin-exacerbated Respiratory Disease","first-page":"157","author":"Lee","year":"2003"},{"key":"10.1016\/j.rmed.2018.01.002_bib176","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaci.2013.11.016","article-title":"Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"133","author":"Woessner","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib177","first-page":"448","article-title":"Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease","volume":"20","author":"Bobolea","year":"2010","journal-title":"J. Invest. Allergol. Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib178","doi-asserted-by":"crossref","unstructured":"E. Phillips-angles, P. Barranco, M. Lluch-bernal, J. Dominguez-ortega, V.L. Np, S. Quirce, Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab, J. Allergy Clin. Immunol. Pract. (n.d.) 1\u20134. doi:10.1016\/j.jaip.2016.12.013.","DOI":"10.1016\/j.jaip.2016.12.013"},{"key":"10.1016\/j.rmed.2018.01.002_bib179","doi-asserted-by":"crossref","unstructured":"B. Aerd, S.N. Hospital, T.E. Committee, S.N. Hospital, G. Evaluation, T. Effectiveness, Omalizumab reduces cysteinyl leukotriene and 9a,11b-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease, (n.d.). doi:10.1016\/j.jaci.2015.09.034.","DOI":"10.1016\/j.jaci.2015.09.034"},{"key":"10.1016\/j.rmed.2018.01.002_bib180","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaip.2015.01.012","article-title":"Omalizumab in the treatment of aspirin-exacerbated respiratory disease","volume":"3","author":"Bergmann","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1016\/j.rmed.2018.01.002_bib181","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.01.002_bib182","series-title":"Dupilumab in Persistent Asthma with Elevated Eosinophil Levels","author":"Wenzel","year":"2013"},{"key":"10.1016\/j.rmed.2018.01.002_bib183","article-title":"Aspirin-exacerbated respiratory disease and current treatment modalities","author":"Sakalar","year":"2016","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"10.1016\/j.rmed.2018.01.002_bib184","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-8-16","article-title":"Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation","volume":"8","author":"Uller","year":"2007","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2018.01.002_bib185","unstructured":"Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00555971. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib186","unstructured":"Effect of Mepolizumab in Severe Bilateral Nasal Polyps. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03085797. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib187","unstructured":"Mepolizumab in Nasal Polyposis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01362244. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib188","unstructured":"An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920893. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib189","unstructured":"A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-24). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02912468. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib190","unstructured":"Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00843193. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib191","unstructured":"Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (MESOS). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02449473. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib192","unstructured":"A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01987492. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib193","unstructured":"Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01902290. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib194","unstructured":"Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) (Aspirin). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597375. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib195","unstructured":"Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03028350. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib196","unstructured":"Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02216357. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib197","unstructured":"Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03326063. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib198","unstructured":"Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02560610. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib199","unstructured":"Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02555683. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib200","unstructured":"One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids (OLIVE). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00758589. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib201","unstructured":"A Study of ARRY-502 in Patients With Persistent Asthma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01561690. (Accessed 8 December 2017), (n.d.)."},{"key":"10.1016\/j.rmed.2018.01.002_bib202","unstructured":"GSK2190915 Moderate to Severe Asthma Study. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00850642. (Accessed 8 December 2017), (n.d.)."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118300039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118300039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:39:15Z","timestamp":1760614755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118300039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":202,"alternative-id":["S0954611118300039"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.01.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin exacerbated respiratory disease: Current topics and trends","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}